Our technologies are designed to provide retinal specialists with innovative treatment approaches, to solve serious and persistent issues facing retinal patients.
Tissue interface accommodates variations in scleral thickness
Semi-automated deployment of microcatheter reliably accesses the suprachoroidal space
Transscleral illumination of microcatheter confirms accurate deployment
Posterior placement of microcatheter adjacent to specific tissues involved in retinal disease
Minimally invasive in-office procedure with small-gauge needle insertion
Does not penetrate the intraocular space
Enables safe, routine drug administration
Drug delivery only occurs after visual confirmation of correct microcatheter placement (ensures accurate drug delivery)
Delivers drug products alongside the posterior retina and macula
Our development products incorporate our proprietary Oxuspheres™ drug-containing, biodegradable polymer system. Oxuspheres are designed to deliver clinically therapeutic drug levels over prescribed treatment periods to the target tissues involved in retinal disorders, while maintaining low drug levels elsewhere in the eye to minimize off-target drug side effects.
Oxusphere drug products provide sustained drug treatments and have the potential to address significant unmet needs by improving patient outcomes and dramatically reducing the unsustainably high treatment burden for patients, retinal specialists, and healthcare systems.
Safe, biodegradable, sustained-release drug product
Highly tunable to independently adjust dosing and duration
Designed to perform in targeted small spaces in the eye, such as the suprachoroidal space
Well suited for a variety of agents
Low-volume preparations avoid reflux, and significant acute elevations in intraocular pressure following administration
Provides sustained treatment for up to one year following a single administration
Long-lasting treatments significantly reduce the number of annual injections and visits for patients and clinicians
Provides targeted drug distribution to the specific tissues involved in retinal diseases
Sustained therapy translates to more consistent treatment and better adherence
Oxulumis® is a minimally invasive, semi-automated administration device for routine delivery of therapeutics via an illuminated microcatheter to the posterior suprachoroidal space of the eye.
Tissue interface accommodates variations in scleral thickness
Semi-automated deployment of microcatheter reliably accesses the suprachoroidal space
Transscleral illumination of microcatheter confirms accurate deployment
Posterior placement of microcatheter adjacent to specific tissues involved in retinal disease
Minimally invasive in-office procedure with small-gauge needle insertion
Does not penetrate the intraocular space
Enables safe, routine drug administration
Drug delivery only occurs after visual confirmation of correct microcatheter placement (ensures accurate drug delivery)
Delivers drug products alongside the posterior retina and macula
Our development products incorporate our proprietary Oxuspheres™ drug-containing, biodegradable polymer system. Oxuspheres™ are designed to deliver clinically therapeutic drug levels over prescribed treatment periods to the target tissues involved in retinal disorders, while maintaining low drug levels elsewhere in the eye to minimize off-target drug side effects.
Oxusphere drug products provide sustained drug treatments and have the potential to address significant unmet needs by improving patient outcomes and dramatically reducing the unsustainably high treatment burden for patients, retinal specialists, and healthcare systems.
Safe, biodegradable, sustained-release drug product
Highly tunable to independently adjust dosing and duration
Designed to perform in targeted small spaces in the eye, such as the suprachoroidal space
Well suited for a variety of agents
Low-volume preparations avoid reflux, and significant acute elevations in intraocular pressure following administration
Provides sustained treatment for up to one year following a single administration
Long-lasting treatments significantly reduce the number of annual injections and visits for patients and clinicians
Provides targeted drug distribution to the specific tissues involved in retinal diseases
Sustained therapy translates to more consistent treatment and better adherence
Our Site
General Contact
+44 (0)1865 636200
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Media Contact
Ben Atwell / Alex Davis
FTI Consulting
London
Limited company registered in England and Wales (Registration No. 09331313)
VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting